Gut microbiome study for lung, melanoma, and gynecologic cancers
Part of Cancer, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study looks at how the bacteria in your gut might affect how well immunotherapy works for certain cancers. It is for people with advanced lung cancer, melanoma, or certain gynecologic cancers who are about to start immunotherapy, and it may help doctors understand why some people respond better than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced non-small cell lung cancer, melanoma, or a gynecologic cancer (endometrial or cervical) that has spread or come back.
- You are about to start your first immunotherapy treatment, either alone or with chemotherapy.
- You are 18 years or older.
- You are able to take care of yourself (up to needing help sometimes, but not bedridden).
- You have not had certain treatments recently, like chemotherapy within the last 28 days or major surgery within the last 3 weeks.
- You do not have an active autoimmune disease that requires steroids or other immune-suppressing medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the bacteria in your gut (microbiome) might affect how well your lung cancer treatment works and what side effects you experience. The goal is to learn if certain gut bacteria can predict treatment response or side effects for people with advanced non-small cell lung cancer.
This study looks at the bacteria in your mouth, gut, and tumors to see if they affect how well first-line immunotherapy works. It is for people with advanced stomach, colorectal, breast, cervical, or head-and-neck cancer.
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study looks at how well immunotherapy works for advanced or recurrent endometrial and cervical cancer by checking certain markers in your blood and tissue. It aims to find out which patients might benefit most from this treatment.
This study looks at how bacteria in your gut, your immune system, and colon cancer interact. It aims to understand these connections to improve future treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.